BioMarin Pharmaceutical Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | $0.31 | $0.32 | $0.31 |
| Q2 2024 | 5 | $0.36 | $0.36 | $0.36 |
| Q3 2024 | 14 | $0.53 | $0.54 | $0.53 |
| Q4 2024 | 17 | $0.48 | $0.60 | $0.55 |
| Q1 2025 | 9 | $0.48 | $0.78 | $0.64 |
| Q2 2025 | 8 | $0.66 | $0.76 | $0.72 |
| Q3 2025 | 4 | $0.71 | $0.82 | $0.78 |
| Q4 2025 | 5 | $0.70 | $0.81 | $0.77 |
| Q1 2026 | 5 | $0.29 | $0.33 | $0.32 |
| Q2 2026 | 3 | $0.26 | $0.30 | $0.29 |
| Q3 2026 | 3 | $0.24 | $0.28 | $0.27 |
| Q4 2026 | 5 | $0.22 | $0.25 | $0.24 |
BioMarin Pharmaceutical Inc. Earnings Date And Information
BioMarin Pharmaceutical Inc. last posted its earnings results on Tuesday, October 29th, 2024. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.13. The company had revenue of 733.87 M for the quarter and had revenue of 2.42 B for the year. BioMarin Pharmaceutical Inc. has generated $1 earnings per share over the last year ($0.87 diluted earnings per share) and currently has a price-to-earnings ratio of 37.49. BioMarin Pharmaceutical Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
BioMarin Pharmaceutical Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | $0.57 | $703.43 M | $733.87 M | ||
| 08/05/2024 | Q2 2024 | $0.36 | $0.56 | 0.2 | $663.98 M | $708.66 M |
| 04/26/2024 | Q1 2024 | $0.47 | $648.83 M | |||
| 02/26/2024 | Q4 2023 | $0.11 | $646.21 M | |||
| 11/02/2023 | Q3 2023 | $0.21 | $603.84 M | $585.97 M | ||
| 08/02/2023 | Q2 2023 | $0.30 | $595.23 M | $594.60 M | ||
| 04/28/2023 | Q1 2023 | $0.27 | $592.95 M | |||
| 02/27/2023 | Q4 2022 | -$0.07 | -$0.00 | 0.07 | $537.54 M | |
| 10/28/2022 | Q3 2022 | -$0.04 | $518.45 M | $505.34 M | ||
| 08/04/2022 | Q2 2022 | $0.15 | $520.20 M | $533.80 M | ||
| 04/29/2022 | Q1 2022 | $0.63 | $519.36 M | |||
| 02/25/2022 | Q4 2021 | -$0.32 | $449.81 M | |||
| 10/29/2021 | Q3 2021 | -$0.20 | $435.30 M | $408.74 M | ||
| 07/30/2021 | Q2 2021 | $0.07 | $448.31 M | $501.69 M | ||
| 04/30/2021 | Q1 2021 | $0.10 | $486.03 M | |||
| 02/26/2021 | Q4 2020 | $0.12 | $452.12 M | |||
| 11/06/2020 | Q3 2020 | $4.33 | $457.38 M | $476.78 M | ||
| 08/04/2020 | Q2 2020 | -$0.16 | $418.62 M | $429.49 M | ||
| 05/01/2020 | Q1 2020 | $0.45 | $502.07 M | |||
| 02/27/2020 | Q4 2019 | $0.08 | $454.44 M |
BioMarin Pharmaceutical Inc. Earnings: Frequently Asked Questions
-
When is BioMarin Pharmaceutical Inc.'s earnings date?
BioMarin Pharmaceutical Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
-
Did BioMarin Pharmaceutical Inc. beat their earnings estimates last quarter?
In the previous quarter, BioMarin Pharmaceutical Inc. (:BMRN) reported $0.91 earnings per share (EPS) to beat the analysts' consensus estimate of $0.78 by $0.13.
-
How can I listen to BioMarin Pharmaceutical Inc.'s earnings conference call?
The conference call for BioMarin Pharmaceutical Inc.'s latest earnings report can be listened to online.
-
How can I read BioMarin Pharmaceutical Inc.'s conference call transcript?
The conference call transcript for BioMarin Pharmaceutical Inc.'s latest earnings report can be read online.
-
How much revenue does BioMarin Pharmaceutical Inc. generate each year?
BioMarin Pharmaceutical Inc. (:BMRN) has a recorded annual revenue of $2.42 B.
-
How much profit does BioMarin Pharmaceutical Inc. generate each year?
BioMarin Pharmaceutical Inc. (:BMRN) has a recorded net income of $2.42 B. BioMarin Pharmaceutical Inc. has generated $0.89 earnings per share over the last four quarters.
-
What is BioMarin Pharmaceutical Inc.'s price-to-earnings ratio?
BioMarin Pharmaceutical Inc. (:BMRN) has a price-to-earnings ratio of 37.49 and price/earnings-to-growth ratio is 0.
